Media
Press Releases
July 19, 2024
Lupin’s Alliance Partner ForDoz Receives U.S. FDA Approval for Doxorubicin Hydrochloride Liposome Injection
July 16, 2024
Lupin Receives Tentative Approval from U.S. FDA for Sodium Sulfate, Magnesium Sulfate, and Potassium Chloride Tablets
July 12, 2024
Lupin Receives EIR from U.S. FDA for its Dabhasa Facility
July 12, 2024
Lupin Receives Approval from U.S. FDA for Topiramate Extended-Release Capsules
July 9, 2024
Lupin Receives Tentative Approval from U.S. FDA for Empagliflozin, Linagliptin and Metformin Hydrochloride Extended-Release Tablets
June 22, 2024
Lupin Receives EIR from U.S. FDA for its Somerset Manufacturing Facility
June 14, 2024
Lupin Announces Closure of US FDA Inspection at its Injectable Facility with Zero 483 Observations
June 3, 2024
Lupin Launches Doxycycline for Injection USP in the United States
June 3, 2024
Lupin Receives Tentative Approval from U.S. FDA for Letermovir Tablets
Media
Rajalakshmi Azariah
Vice President & Global Head - Corporate Communications
rajalakshmiazariah@lupin.comElise Titan
Director, U.S. Communications
elisetitan@lupin.comSmart Guide
Close
CloseSearch Product